Our top pick for
resTORbio, Inc is a biotechnology business based in the US. resTORbio shares (TORC) are listed on the NASDAQ and all prices are listed in US Dollars. resTORbio employs 10 staff and has a market cap (total outstanding shares value) of USD$11.9 million.
|52-week range||USD$0.86 - USD$17.22|
|50-day moving average||USD$7.3133|
|200-day moving average||USD$2.6582|
|Wall St. target price||USD$3|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.444|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$0|
|Return on assets TTM||-38.47%|
|Return on equity TTM||-66.75%|
|Market capitalisation||USD$11.9 million|
TTM: trailing 12 months
There are currently 560,879 resTORbio shares held short by investors – that's known as resTORbio's "short interest". This figure is 24.7% down from 744,667 last month.
There are a few different ways that this level of interest in shorting resTORbio shares can be evaluated.
resTORbio's "short interest ratio" (SIR) is the quantity of resTORbio shares currently shorted divided by the average quantity of resTORbio shares traded daily (recently around 683998.7804878). resTORbio's SIR currently stands at 0.82. In other words for every 100,000 resTORbio shares traded daily on the market, roughly 820 shares are currently held short.
However resTORbio's short interest can also be evaluated against the total number of resTORbio shares, or, against the total number of tradable resTORbio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case resTORbio's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 resTORbio shares in existence, roughly 10 shares are currently held short) or 0.0127% of the tradable shares (for every 100,000 tradable resTORbio shares, roughly 13 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against resTORbio.
Find out more about how you can short resTORbio stock.
We're not expecting resTORbio to pay a dividend over the next 12 months.
Over the last 12 months, resTORbio's shares have ranged in value from as little as $0.86 up to $17.22. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while resTORbio's is 2.433. This would suggest that resTORbio's shares are significantly more volatile than the average for this exchange and represent a higher risk.
resTORbio, Inc., a clinical-stage biopharmaceutical company, develops medicine to treat aging-related diseases. Its lead program is selectively inhibits the target of rapamycin complex 1 (TORC1), an evolutionary conserved pathway that contributes to the age-related decline in function of various organ systems, including immune, neurologic, and cardiac functions. The company's lead drug candidate is RTB101, an oral, selective, and potent inhibitor of TORC1 that is in Phase 1b/2a clinical trial for the treatment of Parkinson's disease, as well as to treat neurodegenerative diseases. resTORbio, Inc. has collaboration with TrialSpark to investigate RTB-101 for COVID-19 on the Project Covalence platform. resTORbio, Inc. was founded in 2016 and is headquartered in Boston, Massachusetts.
Everything we know about the Sabic IPO, plus information on how to buy in.
Everything we know about the Compass IPO, plus information on how to buy in.
Everything we know about the Marqeta IPO, plus information on how to buy in.
Everything we know about the Pharming Group N.V. IPO, plus information on how to buy in.
Everything we know about the Metromile IPO, plus information on how to buy in.
Everything we know about the CN Energy Group IPO, plus information on how to buy in.
Everything we know about the Huadi International Group IPO, plus information on how to buy in.
Everything we know about the 908 Devices IPO, plus information on how to buy in.
Steps to owning and managing LEGH, with 24-hour and historical pricing before you buy.
Steps to owning and managing LAKE, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.